Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (October 2021)
44 slides from Windtree Therapeutics's investor presentation, Oct 18, 2021
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics Company Overview Octob WINDTREE THERAPEUTICS
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company'
Slide 3: Windtree Therapeutics Highlights
Windtree Therapeutics Highlights G Biopharmaceutical and medical device company with four advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ; WINT) G Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths: *
Slide 4: Windtree Therapeutics Pipeline
Windtree Therapeutics Pipeline SI @ Lead Products FDA Fast Track Istaroxime Designation _(Acute Heart Failure) Potential for Istaroxime Breakthrough (Early Cardiogenic Shock) designation Oral SERCA2a Activators (Chronic HF; potentially HFpEF) FDA, EMA KL4 Surfactant—COVID 19 Orphan Drug for (COVID 1
Slide 5: Strategy for Value Creation
Strategy for Value Creation To be updated once fullassessment of potential Planned Milestones COVID-19impactto trial conductis fuly understood Istaroxime Meet w/FDA Early Cardiogenic Shock Study 4 Data) )--“ an Istaroxime ae Acute Heart Failure Study EOP? Miginto {transition to Phase 3)** Pha, poten
Slide 6: Istaroxime
Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and Early Cardiogenic Shock
Slide 7: Heart Failure — Large, Growing Market But Underserved
Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MUSS., 20M+ worldwide patients > #1 cause of U.S. hospitalization in patients > 65 years old; * >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) > In-patient
Slide 8: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need "= Clinical objectives for AHF patient management include: * Relieve pulmonary congestion and general edema (e.g., “dry out”) with IV diuretics * Improve cardiac function and peripheral/organ perfusion * Achieve stable, fully compensated clinical
Slide 9: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism | of Action > ~ Oss, = Inhibition of the sodium- Stimulation of SERCA2a activity enhances calcium reuptake resulting in potassium pumpandeff
Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary
Istaroxime AHF Phase 2a & 2b Studies — Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients m bh © n=120 Dosing= 6 hour Phase ADHF Patients 0.5, 1, 1.5 ug/kg/min Infusion 2a Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 ue/Wg/min Infusion (dyspnea plus need f
Slide 11: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio“ and Stroke Volume istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo 20 a 10 10 oo 00 10 10 g 2 g $20 B20 Pen ye 30 ‘0 Fe 3 50 so Infusion period Tafusion period ° . _ Pp * p-value = 0.029 * prvalues 0.034 Beene — Sho
Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 2 Soo 9 z 7 — Systolic 5 Blood A Pressure = 6 + (SBP) é SE | 3 5 __TP-value=0.011, ** p-values0:006 ese organo yo oor eros roth =-9 Placeb
Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 yg/kg/min vs. placebo x é 2 “ Infusion period a ee Eo 53 a 26 re) Ban * pwalue = 0.01 Sas sf SF S&S SS s a =-9- Placebo-Cohot 1 —geistaoxime0' ue/Ke/min cTnT —0 to 24 hours 36 9 2 OS wom istaroxime 1.0 g/kg/min vs. placebo Hea
Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring May Have Protective Effect on Cardiac Arrhythmias Clinically Significant Arrhythmias Clinically Significant Arrhythmias 120% —205% 105% 105% 35.0% 200% 2a0% 2a0% 100% aaiag ae 15.0% I 5% 60% fox foo% 100% = 3% 28% 20% P| 50% oom om Bxseine Oe
Slide 15: Istaroxime — Acute Heart Failure Next Steps
Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact
Slide 16: Istaroxime Early Cardiogenic Shock
Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development
Slide 17: Cardiogenic Shock
Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf
Slide 18: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction an
Slide 19: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat hypotension in the setting of shock(?) FDA Regulatory (Precedent: NDA for Gi
Slide 20: Changes in SBP — Phase 2a and 2b Dose Groups
Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 20.0 z 18.0 & 16.0 w 14.0 a + 12.0 & » 10.0 a § 8.0 & 60 & = 40 a 6 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study 0.5 pg/kg/min 1.0 yg/kg/min 1.5 yg/kg/min Study/Dose Mean SBP a
Slide 21: Istaroxime Early Cardiogenic Shock Study
Istaroxime Early Cardiogenic Shock Study Ongoing early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure 0 “60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF in the EU and US 1.0 - 1.5ug/kg/min target d
Slide 22: Next Generation, Oral SERCA2a Activators
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & iw. therapies for chronic heart = “Next generation Istaroxi
Slide 23: Summary
Summary Potential to Create Value = Acute heart failure — large market with significant unmet need * Istaroxime appears to be the only drug in Phase 2 or Phase 3 development for AHF treatment = Istaroxime— dual-mechanism therapy with positive Phase 2a and 2b trial outcomes: Y Improved cardiac functi
Slide 24: Lyo Lucinactant
Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in COVID-19 Patients
Slide 25: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function
COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Uses angiotensin- ACEZissurfacemolecule on Surfactant is necessary for lungs to stay Increased likelihood of converting enzyme 2 alveolar Type 2 lung cells — inflated and for proper gas exchange; mechanical venti
Slide 26: Surfactant Administration in Severe COVID-19 Lung Injury
Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = Synthetic KL4 surfactant may mitigate surfactant deficiency wail and resist widespread surfactant destruction that can occur as a result of COVID-19 = Synthetic KL4 surfactant removes any im
Slide 27: Phase 2 Study of Lucinactant for Treatment of COVID-19
Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 Objective: demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS * Up to 20 patients from 4-5 US sites and up to 4 sites in Latin America 7 °
Slide 28: AEROSURF
AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)
Slide 29: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli
Slide 30: AEROSURF — Potential to Impact the Clinical Course of RDS
AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Long-Term Outcomes Reduced Rates and Severity of BPD GS winotRee we Noninvasive RDS treatment Improved Respiratory Study results show Parameters evidence of potential impact on clinical cour
Slide 31: AEROSURF Program Evolution and Strategy
AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach (1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: * Demonstrate that new ADS works and supplement Phase 2 data Optimize dosing with more drug and shorter repeat intervals Y Transitioned
Slide 32: Financial Summary & Capitalization as of June 30, 2021
Financial Summary & Capitalization as of June 30, 2021 = Cash & Equivalents of ~$30.0 million SZ windTREE Common Equivalents Securities as of June 30, 2021 Common Stock 26,704,456 Options (WAEP $11.30) 3,266,141 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 46,599,399 32
Slide 33: Strategy for Value Generation
Strategy for Value Generation Se we WINDTREE THERAPEUTICS” G Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts @& Transactions: * Secure focused BD transactions for deal revenue and
Slide 34: Windtree Therapeutics
Windtree Therapeuti “Striving to Deliver Hope for a Lifetime!” Se windTREE ue
Slide 35: Appendix
Appendix
Slide 36: Acute Heart Failure
Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state
Slide 37: Istaroxime Phase 2a (HORIZON-HF) Study
Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo- 1 cs E controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: * LVEF < 35% * SBP 90-150
Slide 38: Istaroxime Phase 2b Adverse Events
Istaroxime Phase 2b Adverse Events Pooled placebo {n=39) All adverse events 723 (59.0%) Adverse events leading to discontinuation 2G6%) Serious adverse events 2 (5.1%) Cardiogenic shock : Cardiac failure 4 (2.6%) Renal embolism : Transient ischemic attack 1 (2.6%) 4 (2.6%) 4 (2.6%) ‘Adverse Drug Rea
Slide 39: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study
KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza ® Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur
Slide 40: Evidence of KL4 Surfactant Potential Utility in COVID-19
Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic Demonstrated Utility of
Slide 41: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange “4 Initial treatment options include £ 4 Penn seins = invasive and nonin
Slide 42: Windtree Technology Platform — AEROSURF
Windtree Technology Platform — AEROSURF® Proprietary Synthetic KL4 Surfactant Structurally similar to human lung surfactant Liquid KLs surfactant (intratracheal instillate) for RDS approved by the FDA Lyophilized KLs surfactant currently being developed for AEROSURF Utilizing pressure and heated cap
Slide 43: Transformative Potential of AEROSURF
Transformative Potential of AEROSURF® RISKS Surfactant Therapy Reversing surfactant deficiency has a profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumonia cord damage, asthma, lung damage ncPAP Respiratory
Slide 44: Business Development Focus
Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Mid-term Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out
Windtree Therapeutics — Investor Presentation (October 2021) on 6ix